SCYNEXIS Inc

Type: Company

Name: SCYNEXIS Inc

First Reported 11/03/2009 - Updated 11/03/2009 - 3 Documents

SCYNEXIS' SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents

--In Vitro Results presented in a poster session at AASLD; Phase 2 combination studies to be initiated in 2Q 2010--Drug discovery company SCYNEXIS, Inc. today presented positive data from an in vitro study evaluating the antiviral activity of SCY-635 ... [FinanzNachrichten.de - 11/03/2009]

Entities: SCYNEXIS Inc, Antiviral, Polymerase, investigational

First Reported 10/29/2009 - Updated 10/29/2009 - 2 Documents

Supportive data from a preclinical study of SCY-635 to be presented

Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American ... [News-Medical.Net - 10/29/2009]

Entities: SCYNEXIS Inc, Polymerase, Antiviral

First Reported 11/04/2009 - Updated 11/04/2009 - 1 Documents (in Internet & IT)

SCYNEXIS Receives Merial Research Collaboration Milestone Payment

RESEARCH TRIANGLE PARK, N.C. & DULUTH, Ga.--(BUSINESS WIRE)--Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began ... [Business Wire - 11/04/2009]

Entities: SCYNEXIS Inc, Pharmaceutical Area, Peter Hanson, Jurisprudence

First Reported 11/05/2009 - Updated 11/05/2009 - 1 Documents (in Internet & IT)

SCYNEXIS earns payment for meeting certain milestones in multi-year research collaboration with Merial

Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005. SCYNEXIS, a premier drug discovery and development company, ... [News-Medical.Net - 11/05/2009]

Entities: SCYNEXIS Inc, Pharmaceutical Area, Peter Hanson

First Reported 10/27/2009 - Updated 10/27/2009 - 1 Documents

Merck & Co Inc

SCYNEXIS Receives Milestone Payment in Oncology Collaboration with Merck & Co., Inc.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. today announced that it has received a payment from Merck & Co., Inc. for achieving a preclinical milestone resulting from a collaboration to discover and develop novel ... [Business Wire - 10/27/2009]

Entities: SCYNEXIS Inc, Merck & Co Inc, Oncology

First Reported 10/28/2009 - Updated 10/28/2009 - 1 Documents

SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD Annual Meeting

AASLD RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Companys lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster ... [Business Wire - 10/28/2009]

Entities: SCYNEXIS Inc, Polymerase, Antiviral

First Reported 10/28/2009 - Updated 10/28/2009 - 1 Documents

Scynexis Achieves Merck Milestone

Scynexis, Inc. has received a payment from Merck for achieving a preclinical milestone in the companies oncology drug discovery and development collaboration. We are pleased to celebrate success in reaching another milestone with our valued partner, Merck, ... [Contract Pharma - 10/28/2009]

Entities: SCYNEXIS Inc, Doctor of Philosophy, Oncology

First Reported 10/16/2009 - Updated 10/16/2009 - 1 Documents (in Internet & IT)

Fall Edition â09

SCI provides expert pharmaceutical contract services as follows:Analytical Testing Our modern laboratories provide a broad range of quality control, method development, validation, HPLC, GC, GC/MS, dissolution, and product support analytics.Stability ... [Drug Discovery Online - 10/16/2009]

Entities: International Organization for Standardization, SCYNEXIS Inc, One 2 One Inc

Log in to Silobreaker

Advanced Search Options

SCYNEXIS Inc